CryoCath Announces Fiscal 2008 Third Quart...( http://www.cryocat Toronto Sto...),Health

http://www.cryocath.com

Toronto Stock Exchange Symbol: CYT

MONTREAL, Aug. 5 /PRNewswire-FirstCall/ - CryoCath(R) Technologies Inc., the global leader in cryotherapy products to treat cardiac arrhythmias, today announced financial results for the third quarter, ended June 30, 2008.

Selected Third Quarter Financial and Operational Highlights:

- Grew revenue in Q3 2008 to $9.2 million or a 12.0% increase over

comparable electrophysiology (EP) revenue in Q3 2007.

- Continued expansion of active Arctic Front(R) user sites outside the

United States - from 45 at the end of Q2 2008 to 57 at the end of

Q3 2008. Cumulatively, an estimated 3,100 procedures have been

performed with Arctic Front.

- Increased the number of installed consoles worldwide by 28 in Q3 2008

to a total of 547 consoles (net of IDE consoles).

- Achieved significant growth of the Company's flagship AFib products,

led by Arctic Front with sales 76.3% over the same quarter last year.

- Reached a gross profit of 56.2% in Q3 2008, which represents the

third consecutive quarter of gross profit improvement.

- Achieved key milestone of full enrollment and treatment of all

required patients in its pivotal STOP AF IDE Trial in the United

States.

- Introduced Arctic Front in four new jurisdictions: Italy, Belgium,

Spain and Hong Kong, and in Hungary, subsequent to the end of the

quarter.

- Secured gross proceeds of $18.0 million from an equity financing.

- Strengthened operational leadership with the appointments of

Mrs. Ginette Gagne as the Company's Chief Financial Officer during

the third quarter and Mr. Frank Vandeputte as Vice President, Europe,

subsequent to the end of the quarter.

"We have established a clear strategy to focus on co
'/>"/>